Mestag Therapeutics–SEVERAL: investment, 202104 seed financing round $11m with SV Health Investors + JJDC

	Period	2021-04-20
	Successor	Mestag Therapeutics–SEVERAL: investment, 202108 seed financing round extension $34m led by Forbion bringing total seed round to $45m
	Money taker	Mestag Therapeutics Ltd.
	Money source	SEVERAL
	Product	immuno modulatory compound (IMO)
	Product 2	venture capital
	Person	Ashrafian, Houman (SV Health Investors 201810 Partner)

Mestag Therapeutics Ltd.. (4/20/21). "Press Release: Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations across Inflammatory Disease and Cancer". Cambridge.

- Backed by leading healthcare investors including SV Health Investors -

Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”).

The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology.

Mestag’s approach is inspired by landmark studies conducted by a founding team of five leading clinical experts across UK and US, who have uncovered new insights into fibroblast sub-populations:

> Professor Michael B Brenner - Brigham Professor of Medicine at Harvard Medical School and Director of the Human Immunology Center at Brigham and Women’s Hospital, Boston

> Professor David A Tuveson – Director of the Cancer Center and the Roy J Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, Chief Scientist at the Lustgarten Foundation and President of AACR

> Professor Chris Buckley – Kennedy Professor of Translational Rheumatology at the Kennedy Institute of Rheumatology, University of Oxford and Director of NIHR Infrastructure for Birmingham Health Partners

> Professor Soumya Raychaudhuri – Professor of Medicine & Biomedical Informatics, Harvard Medical School & Broad Institute

> Professor Mark Coles – Kennedy Professor of Immunology, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics and Musculoskeletal Sciences and Official Fellow Reuben College, University of Oxford

“Mestag is founded by an incredible team of world leaders in fibroblast biology,” said Susan Hill, PhD, Chief Executive Officer of Mestag “complemented by seasoned drug discovery leaders Ray Jupp PhD, Chief Scientific Officer, previously CSO of immuno-oncology companies EnaraBio and TRexBio, Head of the Immunology TA at UCB and Head of Immunology Discovery at Sanofi Aventis; and James Legg PhD, SVP Research & Early Development, previously SVP Research Crescendo Biologics; as well as Samantha Macro PhD, Head of Finance, previously Head of Group Finance at Horizon Discovery. Their experience will be invaluable as we urgently progress our pipeline of therapeutics towards the clinic.”

Houman Ashrafian, MD, PhD, Managing Partner of SV Health Investors and Executive Chair of Mestag added, “Our commitment to Mestag is a great example of our strategy to seek to build truly innovative companies anchored by exceptional science and experienced teams. The team at SV Health Investors will work in close partnership with the company’s world-leading founders and scientists to develop its business plan and clinical pathway.”

Mestag was founded to develop new medicines for people affected by inflammatory disease and cancer. State-of-the-art single cell analyses enables fibroblasts to be examined with exquisite precision, revealing multiple sub-populations and diverse functionality. Significantly, correlations have been established between fibroblast sub-populations in stromal tissues and disease progression or response to treatment. The discovery of these sub-populations provides us with the opportunity to develop novel therapeutics capable of reverting the phenotype of pathogenic fibroblasts for the benefit of patients.

Mestag founders, Professor Michael Brenner and Professor Chris Buckley, will be presenting at the upcoming conference “Targeting Stromal Cells in Cancer and Inflammatory Diseases” on April 22, 2021.

ENDS

Enquiries

JW Communications
Julia Wilson
Tel: +44 (0)7818 430877

About Mestag:

Mestag was founded in 2020 to develop new medicines for people affected by inflammatory disease and cancer. We develop impactful therapies for patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. Our founder team comprises leading experts in the fields of inflammatory disease, oncology, computational biology and fibroblast biology Professor Michael Brenner, Professor Chris Buckley, Professor David Tuveson, Professor Soumya Raychaudhuri and Professor Mark Coles. Landmark studies by our founders have uncovered multiple fibroblast cell populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag’s investors are SV Health Investors and JJDC and the Company is headquartered in Cambridge, UK. For more information, please visit www.mestagtx.com

About SV Health Investors

SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. The SV family of funds invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.7 billion in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs. For more information, please visit www.svhealthinvestors.com